Helix Tri-Active Therapy Cream Recalled for Manufacturing Quality Deviations
Parker Laboratories is voluntarily recalling Helix Tri-Active Therapy Cream due to manufacturing quality control deviations. The recall affects products with lot numbers A1221010 and A1221011, expiring December 9, 2023, distributed in the United States, Singapore, Korea, and Hong Kong.
What this means for you
Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.
Our severity reasoning: FDA Class II voluntary firm-initiated recall due to manufacturing quality control deviations. No specific health hazard is identified. Fits the rubric for Score 2 as a voluntary precautionary recall.
Plain-English summary
Helix Tri-Active Therapy Cream, manufactured by Parker Laboratories, Inc., is being recalled due to manufacturing quality control deviations. The product is a topical cream containing Camphor 3.2%, Menthol 7.4%, and Methyl salicylate 12.5%, packaged as a 3 fl. oz. roll-on or 4 fl. oz. tube.
The FDA classified this as a Class II recall because of Current Good Manufacturing Practice (CGMP) deviations. Parker Laboratories voluntarily initiated the recall on August 2, 2023.
The affected product was distributed nationwide in the United States, Singapore, Korea, and Hong Kong. Lot numbers A1221010 and A1221011, both expiring December 9, 2023, are included in the recall. The FDA terminated this recall on June 3, 2024.
If you have purchased this product, discontinue use and dispose of it safely. For more information, contact Parker Laboratories, Inc. at 286 Eldridge Road, Fairfield, NJ 07004.
The recalled product
- Product
- Helix Tri-Active Therapy Cream (Camphor 3.2%, Menthol 7.4%, Methyl salicylate 12.5%), packaged in a) 3 fl. oz. roll-on (NDC 30775-052-03) and b) 4 fl. oz. tube (NDC 30775-052-04) Parker Laboratories, Inc. 286 Eldridge Road, Fairfield, NJ 07004
- Manufacturer
- Parker Laboratories, Inc.
- Category
- Drug — Topical / Therapy Cream
- Hazard
- Affected units
- 8
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (4)
- Lot #: a) A1221010
- Exp. Date 12/9/2023
- b) A1221011
- Exp date 12/9/2023
Distribution
Distributed nationwide across the United States.
Part of a larger recall action
This product is one of 5 recalled by Parker Laboratories, Inc. under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 5 products in this recall →Related recalls
Same manufacturer · Parker Laboratories, Inc.
See all →- HighRedux Electrolyte Creme Recalled for Low Viscosity Defect
FDA (Devices) · 2024-05-01
- ModerateFDA Recalls Conductive Adhesive Gel for Viscosity Defect
FDA (Devices) · 2024-03-06
- ModerateDrug manufacturer recalls Protex hand sanitizer due to manufacturing quality deviations
FDA (Drugs) · 2023-08-30
- ModerateFDA Recalls Helix CBD Clinical Cream for Manufacturing Process Violations
FDA (Drugs) · 2023-08-30
- ModerateHelix Pain Relieving Cream recalled nationwide for manufacturing process violations
FDA (Drugs) · 2023-08-30
Same hazard · cgmp deviation
See all →- SevereBaxter Recalls Daptomycin Injection Due to Manufacturing Deviations
FDA (Drugs) · 2026-09-09
- HighBaxter Recalls Clindamycin Injection Due to Manufacturing Deviations
FDA (Drugs) · 2026-09-09
- SevereBaxter Recalls Vancomycin Injection Due to CGMP Deviations
FDA (Drugs) · 2026-09-09
- HighBaxter Recalls Clindamycin Injection Due to Manufacturing Deviations
FDA (Drugs) · 2026-09-09
- SevereBaxter Recalls Vasopressin Injection Due to Manufacturing Deviations
FDA (Drugs) · 2026-09-09